Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Bernard Escudier, Tim Eisen, Walter M. Stadler et al. · New England Journal of Medicine · 2007 · 4.8K citations · Full text

Medicine, Nephrology, Oncology +11

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology · 2008 · 3.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Melody Cobleigh, Charles L. Vogel, Debu Tripathy et al. · Journal of Clinical Oncology · 1999 · 2.8K citations

Medicine, Oncology, Pharmacology +17

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

Ingo K. Mellinghoff, Maria Y. Wang, Igor Vivanco et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text

Medicine, Molecular Medicine, Oncology +16

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Mark J. Ratain, Tim Eisen, Walter M. Stadler et al. · Journal of Clinical Oncology · 2006 · 1K citations · Full text

Medicine, Oncology, Pharmacotherapy +12